| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 655.46 | 6.8% | 31.4% |
| Total Income | 665.21 | 7.2% | 31.3% |
| Expenditure | 585.32 | 7.3% | 29.2% |
| PBT | 79.89 | 6.3% | 48.9% |
| Net Profit | 56.85 | 3.3% | 55.8% |
| OPM | 26.82% | 0.93pp | 0.48pp |
| NPM | 8.55% | 0.32pp | 1.35pp |
| EPS | 1.65 | 15.4% | 75.5% |
Facility expansion and execution drive 56% PAT growth; capex guidance hiked
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Hit H1 facility target (39 delivered, tracking revised 65 plan). EBITDA margins stable as guided despite greenfield drag. SSSG beat 12-16% range.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Dr. Agarwal's delivered strong 56% PAT growth on 31% revenue with upward revisions to facility (60→65) and capex (₹400→500Cr) guidance. Greenfield playbook maturing; SSSG beats guidance at 18.8%. Key risk: ₹42Cr greenfield losses and execution delivery on 65 facilities amid aggressive expansion could compress margins further if ramp-up slows.
₹655.5 Cr
Revenue · +31.4% YoY₹56.9 Cr
Reported PAT · +55.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue from operations rose 31.4% YoY to ₹655 Cr
METDelivered result: ₹655.5 Cr, YoY +31.4%
PAT grew 55.8% YoY to ₹57 Cr for Q2
METDelivered result: ₹56.9 Cr, YoY +55.8%
PAT margin expanded to 8.5% in Q2 FY27
METDelivered NPM 8.6% (rounding difference)
18 new surgical facilities added in Q1, highest ever in single quarter
METConfirmed; total H1 additions 39 (18+21), exceeding prior 60 guidance track
SSSG at 18.8% for Q2 FY27 shows mature network has room to grow
METH1 SSSG 17.7%, Q2 18.8% — both exceed prior 12-16% guidance range
Greenfield losses of ~₹42 Cr cumulatively in H1 while margins stay stable
METEBITDA margin 28.2% H1 despite stated greenfield drag; math consistent
COGS staying in 21-22% range despite volume/mix shifts
METGross margin 78.9% implies COGS ~21%, consistent with stated range
Surgical center strategy will drive higher yields than total-center approach
METSurgical centers contribute ~80 lakhs per month; stated as ₹75-80K range
Earnings quality
What changed since the last call
Facility guidance raised
Upgrade60→65 total facilities; 40→55 surgical centers. Reflects strong H1 execution (39 delivered) and accelerated pipeline visibility.
CapEx guidance raised
Upgrade₹400Cr→₹500Cr to fund 65 vs 60 facility expansion. Shows conviction in Greenfield model despite losses.
Margin outlook maintained
NeutralEBITDA 28.2% stable despite ₹42Cr greenfield losses. No cut, no improvement guidance — holding line.
SSSG beat range
UpgradeDelivered 17.7% H1, 18.8% Q2 vs 12-16% guidance. Mature network still strong; mature facility contribution 75% of group revenue.
Acquisition strategy clarified
NewSelective bolt-on approach (₹55Cr for Dr. Anchal Gupta's 2 centers). Not aggressive; fits expansion plan, especially Delhi-NCR consolidation.
The Q&A
Analysts pressed hard on facility mix (surgical %-age, new vs mature), capex quantum, and execution cadence. Management held firm but requested follow-ups on attrition specifics and fellowship retention. Q&A tone was direct; no major evasions except on regulatory headwinds (deferred to future). Confidence in ramp-up came through.
Acquisition strategy & profile — Harith Ahamed, Avendus Spark
AnsweredYes, selective bolt-ons at right multiples in newer markets. Dr. Anchal Gupta's 2 centers in Delhi for ₹55Cr delivered ₹13.5Cr revenue, ₹7.1Cr EBITDA; 12-month payback. Strategy is organic + selective partnerships.
Capex guidance revision logic — Harith Ahamed, Avendus Spark
AnsweredRaising from ₹400Cr to ₹500Cr. Q1 had ₹400Cr guidance; now revising up to 55 surgical centers (from 40). Momentum in pipeline strong; confidence to accelerate.
Facility expansion pace sustainability — Nikhil Upadhyay, SIMPL
AnsweredPlanning happens 12-18 months in advance. In FY25, identified many sites; leases signed. Pipeline now 100 centers at various stages, filtered to 60 target. FY26 openings (96Cr revenue, 21% of mix) and FY25 (127Cr, 20%) show ramp works. Confidence from breakeven hit in many new markets.
High-end surgical mix and yield — Maulik, 360 ONE Capital
AnsweredMarket moving from LASIK to lenticular procedures (advanced refractive). Femto cataract 25.5% growth, Retinal +26.5%. High-end mix was 18% FY24, now ~30% — won't reach 50-60%. Sustained uptick as insurance penetration rises; disposable incomes up.
COGS and yield trends — Maulik, 360 ONE Capital
AnsweredCOGS staying 21-22% range. High-end procedures (cataract 30% of volume) already reflected. Won't significantly improve as mix is stabilizing. Premiumization ongoing but measured.
Facility ramp economics and losses — Maulik, 360 ONE Capital
PartialFY26 vintage 96Cr revenue, 20.9% growth (still ramping). FY25 at 127Cr, 67.8% growth. FY27 cohort will be ₹18.2Cr (6m loss) and FY26 ₹20.1Cr (6m loss). As utilization scales, losses narrow. Greenfield model proven; new centers hit breakeven faster in established markets.
Depreciation & capex impact on margins — Maulik, 360 ONE Capital
AnsweredYes, broadly that range as capex ₹500Cr deploys over FY27. Margins will absorb this; no specific uplift promised.
Doctor attrition and retention — Diya Shah, Alder C Mehta Investment
PartialOverall ~14-15%, but don't want to quantify by level. Senior level ~1-2%. Will follow up with exact numbers (6-month detail). Similar across regions.
Fellowship conversion and retention — Diya Shah, Alder C Mehta Investment
DodgedWill come back with details. Haven't shared this metric yet; needs validation.
Regulatory risk on drugs and devices — Harith Ahamed, Avendus Spark
DodgedWork with multinationals; Sun Pharma is small part of supply chain. No impact foreseen. On regulatory risk: too early to comment on government intent on IOL pricing; will update as clarity comes.
Vintaging and performance variance — Gopal Bhatt, Baroda BNP Paribas
AnsweredFY24 is early ramp. FY25 has benefit of one acquisition (Punjab Third facility — large asset). Excluding that, FY24 performs better. FY26 vintage in early ramp; FY27 will follow similar trajectory with headroom for growth.
Regional expansion pace — Delhi NCR focus — Nikhil Upadhyay, SIMPL
AnsweredYes. Already 15 centers in 15 months (since Q1 FY26). Micro-market response strong. Will add 8-12 more over 9-12m. Pipeline visibility high; lease agreements in place.
Surgical lens consumption trend — Shubh Kalra, Asit C Mehta Investment
AnsweredVolume + mix (higher-end Femto cataract, lenticular procedures). COGS staying 21-22%; no significant movement vs revenue. Lens costs staying inline with surgical growth.
Guidance
FY27 facility additions now 65 (from 60); surgical centers 55 (from 40)
HighH1 delivered 39 facilities (18+21); tracking ahead of 30 H2 plan. 55 surgical centers shows strategic shift toward higher-margin procedures. Execution track record strong.
EBITDA margin stable ~28% despite greenfield ramp
MediumH1 margin 28.2%; ₹42Cr greenfield losses offset. Depends on ramp velocity in H2 and mix stability. Finance costs rising (₹46Cr post-acquisition) could pressurize margin further.
COGS expected to stay 21-22% range
HighQ2 COGS 21.3%. Premium mix (high-end cataract ~30%) already embedded. No material improvement expected from further mix shift.
CapEx revised to ₹500Cr from ₹400Cr
HighFunding 65 vs 60 facility expansion, including 2 acquisitions (Dr. Anchal Gupta). Pipeline visibility strong; lease agreements in place; management confident in 26 H2 additions.
Risks the call surfaced
Greenfield execution & loss absorption
Medium51 new surgical facilities opened past 12m, contributing ₹42Cr cumulative losses (FY27 ₹18.2Cr, FY26 ₹20.1Cr). Ramp-up to profitability depends on utilization velocity. H2 adds 26 centers; slower-than-expected payback could pressurize EBITDA margins.
Capex intensity & debt serviceability
MediumCapEx raised to ₹500Cr from ₹400Cr (25% increase). Acquisition of Dr. Anchal Gupta's 2 centers added ₹55Cr debt (₹33Cr upfront). Finance costs jumped to ₹46Cr from ₹37Cr Q1. Sustained high capex may require more leverage; refinancing risk if rates rise.
Regulatory scrutiny on pricing
MediumGovernment policy debate on intraocular lens (IOL) markups and drug pricing (Sun Pharma halt on eye drops). Recent court interventions on device pricing. Dr. Agarwal's not directly exposed (non-drug, non-equipment manufacturer), but supply-side constraints or price controls could pressurize margins.
Talent acquisition & attrition in new markets
LowOpening 65 facilities (vs prior 60) requires accelerated hiring of specialists, surgeons, nursing staff. Overall attrition ~14-15%; senior level ~1-2%. Risk: new market entry (Delhi, Pune) may face localized talent scarcity or retention challenges.
Competitive intensity in mature markets
LowSouthern region (62% of revenue) seeing competitive entry in cataract and refractive (Apollo, Narayana, Vision India). Pricing pressure risk in Tier-1 cities (Chennai, Bangalore). West region growth (30% YoY) also seeing new entrants in Mumbai micro-markets.
Management
Score 7/10. Clear, numbers-backed. CEO Adil Agarwal articulate on strategy (Greenfield focus, facility mix shift, acquisition selectivity). CFO Yashwanth provides deep financial detail (COGS, depreciation, vintage analysis). Some hedging on attrition and fellowship retention; deferred specifics but committed to follow-up. Track record strong: Hit H1 facility additions (39 vs 30 target), SSSG beats guidance (17.7% vs 12-16% range), EBITDA margin stable (28.2%) despite greenfield ramp. Revenue growth 31.4% aligned with guidance. Only shortfall: QoQ PAT growth flat (+3.3%), suggesting near-term deceleration.
1 · H2 FY27
Launch 26 additional facilities (targeting 65 total for year); CapEx deploy ₹500Cr
2 · Nov 2026
Merger effective; delisting from BSE/NSE, consolidation into holding company
3 · FY28
Greenfield cohort (FY26-27 openings) reach maturity; margin expansion expected
Key risk: ₹42Cr greenfield losses and execution delivery on 65 facilities amid aggressive expansion could compress margins further if ramp-up slows.
Expansion Blitz Masks Margin Squeeze; the Real Test is H2
PAT surged 56% year-over-year to ₹57 Cr, but quarter-on-quarter growth stalled at +3.3% despite 6.7% revenue growth. Greenfield losses of ₹42 Cr in the first half reveal the real unit economics story.
₹56.9 Cr
+55.8% YoY
₹655.5 Cr
+31.4% YoY
+3.3%
vs +6.7% revenue—margin compression signal
₹42 Cr
51 new facilities opened past 12 months
The headline reads like a breakout quarter. PAT grew 56%, revenue 31%, and management raised both facility guidance (60→65) and capex (₹400→500 Cr). But look at the quarter-on-quarter progression: PAT up just 3.3% despite 6.7% revenue growth. That's the real story—expansion is accelerating, but unit economics are compressing.
The Margin Squeeze
The culprit is greenfield ramp-up. Dr. Agarwal's opened 51 new surgical facilities in the past 12 months and absorbed cumulative losses of ₹42 Cr in H1 FY27 alone (₹18.2 Cr from FY27 vintage, ₹20.1 Cr from FY26 cohort). These centers are maturing—FY26 facilities grew 20.9%, FY25 reached 67.8%—but the burn is front-loaded. EBITDA margin held flat at 28.2%, but that's only because mature facilities (opened before FY23, contributing 75% of revenue) posted 17.2% organic growth. Strip out the mature base, and the new cohort is still underwater.
Claims vs. What Holds Up
Revenue rose 31.4% YoY to ₹655 Cr
PAT grew 55.8% YoY to ₹57 Cr
SSSG at 18.8% beats 12-16% guidance range
39 facilities delivered in H1 (tracking 65 FY27 target)
Greenfield playbook proven; FY25–FY26 cohorts ramping faster
Capex revision and margin stability justified
All major claims corroborated. Revenue, PAT, SSSG, and facility counts match the delivered result. The greenfield execution track is real—older cohorts do ramp. But the implication is understated on the call: new facilities are absorbing losses now, and H2 will add 26 more. That's not a small bet; it's half the annual target, all compressed into a 6-month window.
What Changed on This Call
The revised guidance is a vote of confidence backed by H1 execution (39 facilities landed). But it's also a test: 26 more centers in H2 is the highest velocity ever attempted. Capex raised to ₹500 Cr and finance costs already jumped to ₹46 Cr (from ₹37 Cr in Q1) due to the ₹55 Cr acquisition of Dr. Anchal Gupta's 2-center practice in Delhi. Debt is rising. The margin story depends entirely on ramp velocity.
Bull-Bear Ledger
Bull: Mature network (75% of revenue) growing 17.2% YoY; pricing power intact despite competitive entry
Bull: Greenfield playbook proven; older cohorts show strong ramp (FY25 67.8% growth, FY26 20.9% still early stage)
Bull: Surgical mix premiumization (30% high-end, Femto cataract +25.5% YoY) drives yield expansion
Bull: Pipeline visibility strong; 12-18 month advance planning, 100+ centers in early stages filtered to 65 target
Bear: QoQ PAT growth stalled at +3.3%; sequential deceleration signals near-term ceiling
Bear: Greenfield losses (₹42 Cr H1, ₹18.2 Cr expected H2) are material; if ramp slows, losses extend
Bear: Finance costs rising (₹46 Cr); ₹500 Cr capex may require more leverage
Bear: Regulatory headwinds (IOL pricing, drug scrutiny) deferred; near-term risk timing unclear
Risks, Ranked by Holder Impact
Greenfield execution misses H2 target (26 facilities)
Medium-HighGuidance assumes 26 of 65 FY27 total in 6 months. Slippage compresses annual run-rate and delays profitability. Investors pricing in this execution; miss triggers repricing.
Unit economics deteriorate as ramp velocity slows
Medium-High₹42 Cr H1 losses on 51 centers imply ~₹820 Cr per center. If new markets underperform utilization targets, loss absorption extends and margin pressure intensifies.
Capex and leverage spiral
Medium₹500 Cr capex + ₹55 Cr acquisition debt pushed finance costs to ₹46 Cr. Further capex may require more debt. Rising rates or covenant tightness could constrain expansion.
Regulatory headwind on IOL pricing or drug supply
MediumGovernment policy on intraocular lens markups and Sun Pharma halt cited but impact deferred. Cataract (73% of surgeries) reliant on IOL supply. Price controls or supply constraints could pressurize margins.
Competitive intensity in Tier-1 cities (South/West)
Low-MediumApollo, Narayana, Vision India entering. SSSG beat (17.8%) suggests pricing power intact, but margin compression risk in saturated micro-markets over medium term.
How the Market is Positioned
Dr. Agarwal's trades at ₹537, down 5.5% from its all-time high of ₹568, but still above the 20-day (₹490), 50-day (₹495), and 200-day (₹470) moving averages. The stock has run 34% off its 52-week low, and the market is clearly long. FII ownership holds steady at 58%—institutional conviction is high and stable (up 0.02pp QoQ). Bulk activity in August shows informed buying: ICICI Prudential, Polar Capital (Healthcare Opportunities), Invesco, and Allianz accumulated at ₹501–504. No meaningful insider or promoter selling is flagged.
The -5.5% drawdown from all-time high is modest given the margin-compression risk just revealed on the call. The market has priced in most of the facility expansion upside; the question now is whether the street believes the greenfield playbook holds at 55+ facilities per year. The modest pullback suggests yes, but valuation multiple offers limited margin of safety if H2 execution disappoints.
What to Watch Next
1 · H2 facility delivery pace
Did management land the 26-center target, or did execution slip? Monthly tracking will show whether the greenfield playbook holds at high velocity.
2 · Q3 sequential PAT growth
If QoQ growth rebounds to +6%+ despite more greenfield drag, it signals mature acceleration and mix shift are offsetting losses. Flat or negative growth confirms margin pressure is winning.
3 · FY28 guidance and greenfield loss path
When do cumulative greenfield losses peak and turn positive? FY27 H2 losses of ₹18+ Cr could push cumulative above ₹60 Cr by year-end. Clarify the loss tail and margin recovery timeline.
Dr. Agarwal's delivered on the headline numbers—56% PAT growth is real. But it masks a quarter-to-quarter deceleration that reveals the true tension: expansion is accelerating while unit economics compress. The company is betting that mature-market pricing power and surgical mix premiumization can absorb greenfield losses at a 65-facility-per-year run rate. So far, execution has been strong. But the sequential PAT slowdown says the margin offset isn't keeping pace. H2 will tell whether this is a temporary ramp effect or a structural change.
The stock trades near all-time highs with 58% FII ownership and institutional buying in recent weeks. Valuation offers limited cushion. For new entrants, wait for H2 delivery proof. For holders, the single number to track is Q3 QoQ PAT growth—if it rebounds to +5%+, the margin story stabilizes; if it stays flat or negative, the greenfield playbook needs repricing.